Biotech IPOs Hit 18 in H1 2026 as $670 Million Parabilis Sets Record
Updated
Updated · BioSpace · Jul 15
Biotech IPOs Hit 18 in H1 2026 as $670 Million Parabilis Sets Record
1 articles · Updated · BioSpace · Jul 15
Summary
Eighteen biotech IPOs launched in the first half of 2026, already topping all of 2025’s eight and putting the sector on pace for its strongest year since the pandemic boom.
$670 million Parabilis Medicines and $625 million Kailera reset the record books within weeks, with Parabilis overtaking Kailera as the largest biotech IPO ever after Kailera had passed Moderna’s 2018 mark.
U.S. post-IPO trading has largely held up: seven of 13 newly listed biotechs are above their IPO prices, led by Veradermics, whose shares climbed nearly 550% from its expected $17 opening price to $118 by July 13.
An 18% monthly rise in the XBI in June reflected the backdrop supporting the rebound, including stronger M&A, healthier financing markets, clinical catalysts and a more predictable FDA review process, Truist said.
Two more companies—CRISPR-focused Scribe Therapeutics and metabolic-disease developer Kalohexis—have already filed to go public, and if both list, 2026 would become biotech’s best IPO year since 2021.
In June 2026, Parabilis Medicines, a cancer drug developer from Cambridge, Massachusetts, made headlines by completing the largest biotech IPO on record. The company raised $670 million by selling 33.5 million shares at $20 each, surpassing its initial price range due to strong investor demand. This upsized offering began trading on the Nasdaq under the ticker 'PBLS' and highlighted renewed confidence in the biotech sector. Parabilis’ successful IPO not only set a new benchmark for the industry but also reflected the market’s enthusiasm for innovative companies with promising drug development pipelines.